Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) has announced a conference call and webcast to discuss its second quarter 2024 financial results on August 1, 2024, at 8:30 a.m. ET. Investors can pre-register for the call, and a live audio webcast with accompanying slides will be available on the company's website. A replay will be accessible for 90 days following the event.

Apellis is a global biopharmaceutical company focused on developing therapies for challenging diseases. They have introduced the first new class of complement medicine in 15 years and have two approved medicines targeting C3, including the first-ever therapy for geographic atrophy, a leading cause of blindness worldwide. The company aims to further explore C3 targeting across retinal, rare, and neurological diseases.

Positive

• Apellis has two approved medicines targeting C3
• The company developed the first-ever therapy for geographic atrophy, a leading cause of blindness

Negative

• None.

WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:30 a.m. ET.

To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.

About Apellis 
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178

FAQ

When will Apellis Pharmaceuticals (APLS) report its Q2 2024 financial results?

Apellis Pharmaceuticals (APLS) will report its second quarter 2024 financial results on Thursday, August 1, 2024, during a conference call and webcast at 8:30 a.m. ET.

How can investors access Apellis Pharmaceuticals' (APLS) Q2 2024 earnings call?

Investors can access Apellis Pharmaceuticals' (APLS) Q2 2024 earnings call by pre-registering for the call through the provided link. A live audio webcast and accompanying slides will also be available on the company's website.

What are the key therapeutic areas Apellis Pharmaceuticals (APLS) focuses on?

Apellis Pharmaceuticals (APLS) focuses on developing therapies for serious retinal, rare, and neurological diseases, with a particular emphasis on targeting C3 in the complement system.

What is Apellis Pharmaceuticals' (APLS) breakthrough in geographic atrophy treatment?

Apellis Pharmaceuticals (APLS) has developed the first-ever therapy for geographic atrophy, which is a leading cause of blindness worldwide.